Oxford-based allergy specialist CMP Therapeutics Ltd has raised another EUR 1m from Inventages Capital Investments Inc. The funds are part of a Series A round, which saw Inventages invest EUR 1m in the first tranche in December 2005. The company, which develops natural remedies for conditions such as asthma and hay fever, has raised a total of EUR 4.5m with the provision for follow-on capital.
Target Global I closed on €300m in 2015 and is now fully deployed
Existing investor Redalpine also participates in the round for the online ticketing platform
Deal is Sortera's 13th acquisition since it was established in 2006
Alpina began its ERP software buy-and-build platform with the acquisition of Oxaion in 2015